These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34650610)

  • 1. Aducanumab: evidence from clinical trial data and controversies.
    Tampi RR; Forester BP; Agronin M
    Drugs Context; 2021; 10():. PubMed ID: 34650610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
    Vaz M; Silva V; Monteiro C; Silvestre S
    Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.
    Shi M; Chu F; Zhu F; Zhu J
    Front Aging Neurosci; 2022; 14():870517. PubMed ID: 35493943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
    Mukhopadhyay S; Banerjee D
    J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.
    Beshir SA; Aadithsoorya AM; Parveen A; Goh SSL; Hussain N; Menon VB
    Int J Alzheimers Dis; 2022; 2022():9343514. PubMed ID: 35308835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
    Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
    Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aducanumab for the treatment of Alzheimer's disease.
    Tagliapietra M
    Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab.
    Chin E; Jaqua E; Safaeipour M; Ladue T
    Cureus; 2022 Nov; 14(11):e31065. PubMed ID: 36475205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aducanumab: First Approval.
    Dhillon S
    Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review.
    Haddad HW; Malone GW; Comardelle NJ; Degueure AE; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(1):31925. PubMed ID: 35928986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aducanumab in Alzheimer's disease: A critical update.
    Ashique S; Sirohi E; Kumar S; Rihan M; Mishra N; Bhatt S; Gautam RK; Singh SK; Gupta G; Chellappan DK; Dua K
    Curr Med Chem; 2023 Jul; ():. PubMed ID: 37497712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controversies, and the Future.
    Esang M; Gupta M
    Cureus; 2021 Aug; 13(8):e17591. PubMed ID: 34646644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
    Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
    Neurol Ther; 2021 Dec; 10(2):919-940. PubMed ID: 34426940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy.
    Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Saadatpour Z; Wheeler CA; Natelson Love M; Tanwar M
    Front Radiol; 2023; 3():1305390. PubMed ID: 38249159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-amyloid Antibody Therapies for Alzheimer's Disease.
    Park KW
    Nucl Med Mol Imaging; 2024 Jun; 58(4):227-236. PubMed ID: 38932758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
    Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
    Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria.
    Togher Z; Dolphin H; Russell C; Ryan M; Kennelly SP; O'Dowd S
    Int J Geriatr Psychiatry; 2022 Aug; 37(8):. PubMed ID: 35861223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.